| ★ |  Ralinepag Cuts PAH Clinical Worsening Risk by 55%, With Vallerie McLaughlin, MD | ATS 2026 | | 290 | Estados Unidos | |
| 3 |  Étude CADENCE : Résultats prometteurs pour le sotatercept dans une forme rare d'HTAP | Cardio-online @cardio-online9873 | 2.3K | Francia | 87 |
| 12 |  Efdoralprin Alfa Normalizes Alpha-1 Antitrypsin Levels I #ats2026 | | 548 | Estados Unidos | 84 |
| 16 |  La Universitat se suma al Dia Europeu de Dèficit d'Alfa-1 | Universitat de València @universitatvalencia | 481 | España | 84 |
| 7 |  Inhaled Treprostinil for IPF: TETON-1 Phase 3 Results With Steven Nathan, MD | ATS 2026 | | 301 | Estados Unidos | 85 |
| 6 |  Sotatercept May Improve Right Heart Function in #pulmonaryhypertension | | 232 | Estados Unidos | 85 |
| 5 |  Avances terapéuticos en Hipertensión Pulmonar y su impacto en pacientes con comorbilidades | | 209 | Argentina | 85 |
| 20 |  Importante avance contra el cáncer de pulmón en Salamanca | La Gaceta de Salamanca @lagacetadesalamanca | 207 | España | 84 |
| 11 |  Efdoralprin Alfa vs Standard of Care in AATD: Phase 2 ElevAATe Results | | 156 | Estados Unidos | 85 |
| 19 |  Best Practices for Preclinical Thoracic Aortopathy Studies | The Marfan Foundation @themarfanfoundation | 130 | Estados Unidos | 84 |
| 13 |  Demystifying Evidence for Antiplatelet De-escalation in ASCVD | Matt Lillyblad, PharmD, BCCCP, BCCP | Minneapolis Heart Institute Foundation @mplsheartinstfound | 117 | Estados Unidos | 84 |
| 18 |  Mepolizumab Reduced COPD Hospitalizations in Eosinophilic Disease | ATS 2026 With Gerard Criner, MD | | 113 | Estados Unidos | 84 |
| 2 |  Sotatercept May Improve RV Function in Group 3 3 Pulmonary Hypertension | | 112 | Estados Unidos | 87 |
| 14 |  AERIFY: Phase 3 Data Reveal Challenges, Potential of Itepekimab in COPD | | 105 | Estados Unidos | 84 |
| 8 |  Efdoralprin Alfa vs Standard of Care in AATD: Phase 2 ElevAATe Results | | 82 | Estados Unidos | 85 |
| 9 |  ATS 2026 Asthma Updates: Tezepelumab, Dupilumab, OCS Reduction & More | HCPLive Expert Interviews | | 70 | Estados Unidos | 85 |
| 15 |  Hipertensión pulmonar en Puerto Rico : Diagnóstico tardío y factores de riesgo | | 69 | Puerto Rico | 84 |
| 1 |  ATS 2026 Pulmonology: AD109, Ralinepag, ALIS, Itepekimab & More | HCPLive Expert Interviews | | 55 | Estados Unidos | 89 |
| 4 |  Screening and treatment of systemic sclerosis-associated PAH: where do we stand in 2024? | | 53 | — | 87 |
| 10 |  SGLT2 Inhibitors May Reduce COPD Readmissions I ATS 2026 | | 48 | Estados Unidos | 85 |
| 17 |  Navigating a New Era of PH Management as an APP, With Susanne McDevitt, DNP | | 15 | Estados Unidos | 84 |